Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:47 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenosine Clear all
Completed No phase listed Observational

Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital

NCT02948335
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Nov 3, 2026, 5:47 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Mendelian Reverse Cholesterol Transport Study

NCT01782027
View directory record Official record
Conditions
Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions
3H-cholesterol bound to albumin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 5:47 PM EST
Completed Early Phase 1 Interventional

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

NCT04521569
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

NCT02999984
View directory record Official record
Conditions
Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Days to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

NCT05009199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[18F]MNI-444
Drug
Lead sponsor
Invicro
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Nov 3, 2026, 5:47 PM EST
Terminated Phase 3 Interventional Results available

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

NCT03642132
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 3, 2026, 5:47 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

NCT00859833
View directory record Official record
Conditions
Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions
Adenosine, Regadenoson
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 88 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 3 Interventional

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1Phase 2 Interventional Results available

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02509546
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
8-Chloroadenosine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 5:47 PM EST
Withdrawn Phase 2Phase 3 Interventional

A Clinical Study to Enable Process Validation of Commercial Grade OTL-101

NCT04140539
View directory record Official record
Conditions
Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
OTL-101
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Days to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
View directory record Official record
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 3, 2026, 5:47 PM EST
Not listed Phase 1 Interventional

PBF-1129 in Patients With NSCLC

NCT03274479
View directory record Official record
Conditions
Locally Advanced or Metastatic NSCLC
Interventions
PBF-1129
Drug
Lead sponsor
Palobiofarma SL
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Nov 3, 2026, 5:47 PM EST
Suspended Phase 1 Interventional

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05263284
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
8-Chloroadenosine, Venetoclax
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Caffeine and Cocaine

NCT00733993
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Caffeine 150 MG, Placebo, Amphetamine, Caffeine 300 MG
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 1 Interventional Results available

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

NCT01085201
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Lexiscan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Nov 3, 2026, 5:47 PM EST
Completed No phase listed Observational

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

NCT00833963
View directory record Official record
Conditions
Breast Cancer, Pregnancy
Interventions
Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Nov 3, 2026, 5:47 PM EST
Not yet recruiting Phase 1Phase 2 Interventional

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

NCT05217498
View directory record Official record
Conditions
Spinal Cord Injuries, Myelopathy
Interventions
Istradefylline, low oxygen therapy
Drug · Device
Lead sponsor
Randy Trumbower, PT, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 2 Interventional

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

NCT00376454
View directory record Official record
Conditions
Neuropathic Pain
Interventions
GW493838
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
32
States / cities
Huntsville, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Nov 3, 2026, 5:47 PM EST
Completed No phase listed Observational

Study of Value of Cardiac PET Scans With or Without CT Angiography and/or Measurement of Coronary Flow Reserve

NCT00669968
View directory record Official record
Conditions
Chest Pain, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Intravenous Allopurinol in Heart Failure

NCT00181155
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 5:47 PM EST
Terminated Not applicable Interventional Results available

Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve

NCT03461705
View directory record Official record
Conditions
Coronary; Ischemic
Interventions
Volcano Verrata Pressure Wire, St. Jude Medical (SJM) Aeris Pressure Wire System
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 3, 2026, 5:47 PM EST
Terminated Phase 4 Interventional

Both Exercise and Adenosine Stress Testing

NCT00200629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
Procedure
Lead sponsor
Midwest Heart Foundation
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
20
States / cities
Tucson, Arizona • Roseville, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Nov 3, 2026, 5:47 PM EST
Completed Phase 2 Interventional

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NCT02675829
View directory record Official record
Conditions
Solid Tumor Cancers, Lung Cancer, Bladder Cancer, Urinary Tract Cancers
Interventions
ado-trastuzumab emtansine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 5:47 PM EST